GPC
ESPR

Glacier Peak Capital’s Esperion Therapeutics ESPR Stock Holding History

Glacier Peak Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-38,048
Closed -$376K – 34
2016
Q2 		$376K Hold
38,048
– – 0.4% 30
2016
Q1 		$989K Hold
38,048
– – 0.85% 25
2015
Q4 		$847K Buy
+38,048
New +$960K 0.54% 48

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Glacier Peak Capital's ESPR Position: Q3 2016 in Review

Glacier Peak Capital sold out of Esperion Therapeutics (ESPR) in Q3 2016, closing a stake of 38,048 shares — an estimated $376K sold.

Glacier Peak Capital first reported a position in ESPR in Q4 2015 and held it in 3 quarters. The position peaked at $989K in Q1 2016. 102 funds tracked by Wall St. Rank hold ESPR as of Q3 2016.

  • Glacier Peak Capital reported no remaining Esperion Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Glacier Peak Capital sold 38,048 Esperion Therapeutics shares in Q3 2016, an estimated $376K.
  • Glacier Peak Capital first reported a position in Esperion Therapeutics in Q4 2015 and held it in 3 quarters.
  • Glacier Peak Capital's Esperion Therapeutics position peaked at $989K in Q1 2016.
  • 102 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2016.

Based on Glacier Peak Capital's 13F filing for Q3 2016, filed 14 Nov 2016.